A5058687853- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Long-Term Effects of COVID-19
- Peripheral Neuropathies and Disorders
- Neurological Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Healthcare Systems and Public Health
- Acute Lymphoblastic Leukemia research
- Systemic Sclerosis and Related Diseases
- Cytokine Signaling Pathways and Interactions
- COVID-19 Clinical Research Studies
- Telemedicine and Telehealth Implementation
- Bacillus and Francisella bacterial research
- Medicinal Plants and Bioactive Compounds
- SARS-CoV-2 and COVID-19 Research
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Inflammasome and immune disorders
- Medical and Biological Sciences
- Food Industry and Aquatic Biology
- Vagus Nerve Stimulation Research
- Autoimmune and Inflammatory Disorders Research
- Cerebral Palsy and Movement Disorders
- Viral Infections and Immunology Research
Tyumen Regional Oncological Dispensary
2011-2024
Tyumen State Medical University
2015-2024
Ural State Medical University
2022-2024
Kirov State Medical Academy
2021-2024
Ministry of Health of the Russian Federation
2023
Giprotyumenneftegaz (Russia)
2022
Multiple Sclerosis Center of Atlanta
2020
Primary HealthCare
2019
University of Tyumen
2016-2017
To evaluate the efficacy and safety of anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose 500 mg every 24 weeks during 100 for treatment patients with multiple sclerosis (MS), including relapsing-remitting (RRMS) secondary progressive MS (SPMS) relapses.
To find the optimal therapeutic dose of anti-B cell mAb divozilimab (DIV) based on efficacy and safety data intravenous administration at a 125 mg or 500 in patients with relapsing remitting multiple sclerosis (RRMS) compared to placebo (PBO) teriflunomide (TRF). study DIV within 24 weeks treatment.A multicenter, randomized, double-blind double-masked, placebo-controlled phase 2 clinical trial (CT) BCD-132-2 involved 271 adult RRMS from 25 centres In Russia. Patients were randomly assigned...
To assess the efficacy and safety of sampeginterferon-β1a (samPEG-IFN-β1a) 180 μg 240 administered once every 2 weeks compared to placebo low dose interferon beta-1a (LIB) 30 weekly.Patients with relapsing-remitting multiple sclerosis aged 18-60 years, Expanded Disability Status Scale score ≤5.5 were randomized at a ratio 2:2:2:1 following groups: samPEG-IFN-β1a µg, LIB, placebo. After 20 weeks, group completed study. week 52, final analysis was performed, which included primary endpoint...
To evaluate the efficacy and safety of anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose 500 mg for treatment patients with relapsing-remitting multiple sclerosis (RRMS) in comparison teriflunomide (TRF). The study use drug DIV was carried out 48 weeks therapy.The multicenter, randomized, double-blind double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS included 338 adult RRMS distributed 1:1 ratio into two groups: TRF 14 mg. After...
NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and reimbursed via federal budget program. However, no data about effect reimbursement have been performed so far.
The main results of a medical-sociological study aimed at the evaluation level satisfaction with treatment in patients primary progressive multiple sclerosis (PPMS) are presented. survey was conducted 19 regions Russian Federation and involved 437 confirmed diagnosis PPMS 80 neurologists specialized sclerosis. research carried out by All-Russian Public Organization Disabled People Multiple Sclerosis participation Committee for Treatment Research Sclerosis. This is first involving...
The main target for COVID-19 is the lung with development of acute respiratory failure. But virus also displays tropism to central nervous, muscle, and immune systems. paper gives data available in literature on nervous system damage characteristics clinical magnetic resonance imaging manifestations brain COVID-19. Among neurological symptoms COVID-19, there may be stroke, encephalitis, neuropathy. An account given features multiple sclerosis patient management during pandemic depending risk...
To evaluate an impact of low calorie diet therapy (LCDT) on cerebral hemodynamics, cognitive functions and quality-of-life patients with arterial hypertension chronic ischemia.The main group consisted 22 patients, 16 women 6 men (mean age 54.4±2.4 years), assigned to the diet. The comparison included 20 12 8 55.6±1,0 who received standard antihypertensive treatment. results Doppler ultrasound arteries, were assessed after months treatment.A positive effect LCDT indices maintained for months....
Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications. In last 5 years, there have been several reports severe, sometimes lethal, listeriosis infection in patients treated alemtuzumab. This article presents a clinical case lethal meningoencephalitis, which developed within 7 days after completion first cycle alemtuzumab therapy. January 2018, meeting expert Council was held, at recommendations published 2017 were...
The paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis primary progressive in use ocrelizumab.
To analyze the involvement of immune response genes in pathogenesis primary progressive multiple sclerosis (PPMS).This multicenter study included 111 patients with PPMS from Russian ethnic group. The association system was analyzed by polymorphic variants cytokines and antigen-presenting cells.The genotypes IL-4 (rs2243250)*C/C CLEC16A (rs6498169)*G/G were associated Russians. between HLA-DRB1*15 found out other populations confirmed Russians.Цель исследования. Анализ вовлеченности генов...
The meeting of experts discussed the clinical and pathophysiological features secondary progressive multiple sclerosis (MS) (SPMS), trials, promising treatments for MS stage, as well proposals contributing to improvement current state problem SPMS. In particular, definition criteria SPMS are formulated; earliest period, when its confirmed progression can be recorded, is stated 3 months. exacerbation-unaffected disability 6 months later may considered more convincing. introduction tools early...
For a long time it was believed that pregnancy worsens the clinical course of multiple sclerosis. In several European countries, there have been studies demonstrated remission autoimmune aggression during pregnancy. We studied effect on sclerosi.A retrospective analysis disease 279 patients performed for first in three major Russian centers (Moscow, Novosibirsk, Tyumen).There The use DMT before predictor more favorable after delivery. An earlier beginning delivery led to significant risk...
One of the target areas for development Russian pharmaceutical industry at present is next-in-class drugs medicines. These are original, patent-protected that act on known biological targets, improved or modified in structure and mechanism action compared to existing, successfully proven medicine. The article presents results an expert council management patients with multiple sclerosis place new original medicines JSC BIOCAD company (SamPEG-IFN-β1a divozilimab) therapy algorithm.Одним из...
To evaluate the effectiveness of telerehabilitation (TELEREBT) patients with multiple sclerosis (MS) in context coronavirus pandemic 2020-2021.
To identify the association between cerebrovascular diseases (CVD) and multiple sclerosis (MS) among patients over 50 years old in two independent populations of Moscow Tyumen.
Multiple sclerosis (MS) is an autoimmune-inflammatory and neurodegenerative disease of the central nervous system. The article analyses ability cladribine, which due to its selective lymphotoxic effect on activated cells immunomodulation in brain tissue underwent successful clinical trials 2010, when it was (temporarily) approved Russia. Objective: analyse cladribine tablets daily practice course MS over 3–4 year observational period after immune reconstitution therapy (IRT) several...
Multiple sclerosis (MS) is a chronic autoimmune disease of the nervous system predominantly progressive nature. In addition to diseasemodifying drug therapy MS patients require physical rehabilitation, including tele-rehabilitation (TeleRBT). Objective: evaluate efficacy TeleRBT in as one rehabilitation stages during 2020–2021 coronavirus pandemic. Material and methods . The study involved 36 diagnosed with who completed course. course included 10 lessons 60 minutes each over days two-day...